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Abstract 
Capsaicin applied to human skin provokes a response known as neurogenic inflammation. Neuropeptides 
(substance P, CGRP), released from afferent C-fiber terminals and histamine, secondarily released from 
mast cells, are supposed to participate in this reaction. We investigated the contribution of arachidonic acid 
and metabolic products to neurogenic inflammation, using a potent topically applied glucocorticoid and 
the corresponding vehicle. Arachidonic acid is liberated from membrane phospholipids by phospholipase 
Az, an enzyme that can be blocked by glucocorticoids. In 12 healthy volunteers, neurogenic inflammation 
was induced by capsaicin 1 % on both upper forearms after 16 h of topical pretreatment with either 
prednicarbate or vehicle. Neurogenic inflammation was assessed by laser Doppler flowmetry and by 
planimetry of flare sizes. Prednicarbate significantly reduced the laser Doppler flow values inside the flare 
responses, as well as the flare sizes themselves. These results show that to some extent glucocorticoids 
reduce capsaicin-induced neurogenic inflammation. 
Introduction 
Capsaicin application to the skin causes vasodila-
tation extending beyond the area of application. 
This response is called neurogenic inflammation. It 
is supposed that the visible redness (flare) is due 
to axon reflex vasodilatation via primary afferent 
neurones (C-fibers), having an efferent function, i.e. 
liberating neuropeptides (e.g. substance P, CGRP) 
from their terminals [I]. Besides these neuropepti-
des, other endogenous vasoactive agents have been 
suspected to participate in neurogenic inflamma-
tion. The present study was undertaken in order to 
assess the eventual contribution of arachidonic acid 
to capsaicin-induced neurogenic inflammation. 
Arachidonic acid is liberated from membrane phos-
• Author for correspondence. 
pholipids by phospholipase Az. This process is 
inhibited by glucocorticoids in a complex manner 
[2]. This report is addressed to the following 
questions: 
1. What is the effect of topically applied glucocorti-
coid on capsaicin-induced neurogenic inflamma-
tion in human forearm skin? 
2. Does the inhibition of arachidonic acid liber-
ation from membrane phospholipids influence cap-
saicin-induced neurogenic inflammation? 
Materials and methods 
Pretreatment with prednicarbate cream and 
vehicle cream 
After obtaining informed consent, 12 healthy 
volunteers (aged 22-31 yr) participated in this 
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study, which was approved by the local ethics 
committee. Using a randomized schedule for the 
choice between left and right side, 3 g prednicarbate 
containing cream (Dermatop®, Casella Riedel) and 
3 g vehicle cream (Dermatop® Basiscreme, Casella 
Riedel), respectively, were applied to square areas 
(6 x 6 cm2 ) on both the upper forearms. The cream 
layers were covered with occlusive dressings over-
night for 16 h. Two hours after removal of the 
cream bandages, the skin was pretreated with 
DMSO 10% (Merck) for 1 h to improve capsaicin 
absorption. 
I nduction and assessment of capsaicin-induced 
neurogenic injiammation 
Neurogenic inflammation was induced by 100 JlI 
capsaicin 1 % (Serva) soaked up in a plaster (Hansa-
plast), 13 x 18mm2 , applied to the skin for 25min. 
The extent of the skin reaction to capsaicin was 
assessed by measuring the superficial cutaneous 
blood flow (SCBF) with laser Doppler flowmetry 
(LDF) (PeriFlux PF3, PERIMED, Sweden), and by 
planimetry of flare sizes, i.e. the local visible red-
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ness. A special holder for the LDF probe was used 
defining the positions of 12 measuring points on the 
skin: 4 measuring points inside the application area 
reflecting the direct action of the substance capsai-
cin plus an eventual neurogenic inflammation 
(inside SCBF); 8 peripheral measuring points dem-
onstrating the effects induced by neurogenic in-
flammation only (outside SCBF). Inside SCBF and 
outside SCBF were calculated as the means of the 
respective 4 central and 8 peripheral LDF values. 
In both series SCBF at rest were subtracted from 
the test result. All results are expressed as mean 
± SO. The "Wilcoxon signed rank test" was used 
for statistical analyses (significance level: p < 0.05). 
Results 
SCBF following prednicarbate pretreatment and 
vehicle pretreatment were not significantly different 
before capsaicin application (8.6 ± 1.2 perfusion 
units (p.u.); 9.9 ± 2.3 p.u.). After capsaicin applica-
tion, the prednicarbate pretreated side showed a 
significant reduction of inside SCBF of 18% (72.0 
± 13.3 p.u.; 62.7 ± 16.8 p.u., Fig. 1). Outside SCBF 
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The effect of prednicarbate pretreatment versus vehicle pretreatment on superficial cutaneous blood flow (SeBF) of capsaicin-induced 
neurogenic inflammation. Inside SeBF reflects the direct effects of the capsaicin plus any additional neurogenic inflammation; outside 
seBF is an exclusive measure of neurogenic inflammation. Ordinate scale is in relative units of perfusion. 
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The effect of prednicarbate pretreatment versus vehicle pretreatment on the size of capsaicin-induced flare reaction. Prednicarbate 
reduced the flare sizes significantly by 18%. 
was also significantly reduced by 18 % following 
prednicarbate pretreatment (59.6 ± 17.5 p.u.; 49.1 
± 19.0 p.u., Fig. 1). Further, prednicarbate reduced 
the size of flares significantly by 18% compared 
to vehicle (2280.1 ± 632.4 mm2; 1873.7 ± 555.0mm2, 
Fig. 2). 
Discussion 
The small but statistically insignificant difference 
between SCBF at rest on the corticoid pretreated 
side versus the vehicle side is in accordance with 
Bisgaard et al. [3]. It has been shown that glucocor-
ticoids are capable of reducing the endogenous 
release of arachidonic acid by inhibition of phos-
pholipase A2 [4]. Glucocorticoids are also sugges-
ted to inhibit the synthesis of prostaglandins by 
inhibition of prostaglandin synthase enzyme ex-
pression and by coupling lipocortin to membrane 
phospholipids, in this way reducing the liberation 
of arachidonic acid [2]. In this study, prednicarbate 
diminished neurogenic inflammation (flare size as 
well as SCBF, both significantly by 18%). In inves-
tigations described elsewhere in these proceedings, 
we have shown that treatment with acetylsalicylic 
acid ot indomethacin, i.e. a presumed blockade of 
prostaglandin synthetase, had no effect on capsai-
cin-induced neurogenic inflammation. The effect-
iveness of a glucocorticoid and the ineffectiveness of 
ASA/indomethacin indicates that arachidonic acid 
or related metabolic products other than those 
derived from cyclooxygenase pathway may be in-
volved in the development of neurogenic inflamma-
tion. Another mode of action of the glucocorticoids 
could also explain our results, namely their inhibi-
tion of the expression of Ca2+ -independent NO 
synthase, assuming that the potent endogenous 
vasodilator NO does participate in neurogenic 
inflammation. This line of reasoning derives from 
the finding that, in contrast to constitutive Ca2 + -
dependent NO synthase, the expression of 
Ca2+ -independent NO synthase is inhibited by 
glucocorticoids [5]. 
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